Starovasnik Melissa A. sold $170K of TWST
Starovasnik Melissa A. sold 2,500 shares of Twist Bioscience Corp (TWST) at $68.00 ($0.17M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates insider activity but does not introduce new operational or financial information about TWST.
Market read
Traders may monitor insider activity trends, but this specific filing is unlikely to drive a fresh fundamental repricing.
What to watch
10b5-1 plans are often pre-scheduled; the sale price ($68) and timing may not reflect current valuation views.
Background
SEC Form 4 reports an insider transaction by a director of Twist Bioscience; the transaction was executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Twist Bioscience director Melissa A. Starovasnik sold 2,500 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; treat as routine 10b5-1 selling unless follow-on filings show sustained net selling.
The filing is an ownership-change disclosure only, and the article provides no earnings, guidance, deal, or regulatory catalyst.
Market effects
No sector read-through; this is a single-company insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
If TWST shows a pattern of repeated insider selling across multiple filings, traders may re-rate risk despite 10b5-1 timing.
Key entities
- issuerTwist Bioscience Corp
Subject of the Form 4 insider sale disclosure.
- insiderMelissa A. Starovasnik
Director who sold 2,500 shares on May 28, 2026 under a 10b5-1 plan.
